Myelofibrosis Excellence Forum

Myelofibrosis

Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.

Videos

Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis

12/19/2022

Francesco Passamonti, MD, presents findings from a study on the combination of navitoclax and ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis at the 2022 ASH Annual Meeting & Exposition.

Francesco Passamonti, MD,...

12/19/2022

Oncology

Videos

Efficacy and Safety of Parsaclisib Add-on to Ruxolitinib in Patients With Myelofibrosis

12/12/2022

At the 2022 ASH Annual Meeting and Exposition, Abdulraheem Yacoub, MD, presented final results from a phase 2 study on the efficacy and safety of adding parsaclisib to ruxolitinib therapy in patients with myelofibrosis.

At the 2022 ASH Annual Meeting...

12/12/2022

Oncology

Videos

Ruben Mesa, MD, Discusses Momelotinib in Patients With Myelofibrosis

03/16/2022

Ruben Mesa, MD, discusses the phase 3 MOMENTUM trial evaluating momelotinib in patients with MF who are symptomatic and anemic.

Ruben Mesa, MD, discusses the...

03/16/2022

Oncology

Videos

Addition of Parsaclisib to Ruxolitinib Therapy Shows Promise for Patients With Myelofibrosis

07/02/2020

Abdulraheem Yacoub, MD, discusses the results from a phase 2 study, which evaluated optimal dosing and efficacy of the addition of parsaclisib in patients with myelofibrosis with suboptimal response on ruxolitinib.

Abdulraheem Yacoub, MD,...

07/02/2020

Oncology

Videos

Treatment of Chronic Idiopathic Myelofibrosis

05/08/2020

Ruben Mesa, MD, FACP, provides an update on therapy options for the treatment of chronic idiopathic myelofibrosis.

Ruben Mesa, MD, FACP, provides...

05/08/2020

Oncology

Videos

Navitoclax Plus Ruxolitinib Yields Encouraging Responses in Myelofibrosis

12/16/2019

Jacqueline Garcia, MD, discusses results from a phase 2 study of navitoclax in combination with ruxolitinib for patients with primary or secondary myelofibrosis.

Jacqueline Garcia, MD, discusses...

12/16/2019

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology